Novel insights into the treatment of complement-mediated hemolytic anemias

• Published in: Therapeutic Advances in Hematology Vol. 10; p. 2040620719873321
• Main Authors: Berentsen, Sigbjørn, Hill, Anita, Hill, Quentin A., Tvedt, Tor Henrik Anderson, Michel, Marc
• Format: Book Review Journal Article
• Language: English
• Published: London, England SAGE Publications 01.09.2019; Sage Publications Ltd; SAGE Publishing
• Subjects: Anemia; Autoimmune diseases; Blood diseases; Drug therapy; Erythrocytes; Genetic disorders; Inhibitor drugs; Monoclonal antibodies; Review; paroxysmal nocturnal hemoglobinuria; cold agglutinin disease; complement; complement inhibitors; therapy; autoimmune hemolytic anemia
• ISSN: 2040-6207; 2040-6215
• DOI: 10.1177/2040620719873321

Complement-mediated hemolytic anemias can either be caused by deficiencies in regulatory complement components or by autoimmune pathogenesis that triggers inappropriate complement activation. In paroxysmal nocturnal hemoglobinuria (PNH) hemolysis is entirely complement-driven. Hemolysis is also thought to be complement-dependent in cold agglutinin disease (CAD) and in paroxysmal cold hemoglobinuria (PCH), whereas warm antibody autoimmune hemolytic anemia (wAIHA) is a partially complement-mediated disorder, depending on the subtype of wAIHA and the extent of complement activation. The pathophysiology, clinical presentation, and current therapies for these diseases are reviewed in this article. Novel, complement-directed therapies are being rapidly developed. Therapeutic terminal complement inhibition using eculizumab has revolutionized the therapy and prognosis in PNH but has proved less efficacious in CAD. Upstream complement modulation is currently being investigated and appears to be a highly promising therapy, and two such agents have entered phase II and III trials. Of these, the anti-C1s monoclonal antibody sutimlimab has shown favorable activity in CAD, while the anti-C3 cyclic peptide pegcetacoplan appears to be promising in PNH as well as CAD, and may also have a therapeutic potential in wAIHA.